Mizagliflozin for the treatment of functional constipation: Are new drugs better?
Gastroenterology. 2019 Jan 16;:
Authors: Black CJ, Ford AC
Functional constipation (FC) is a very common disorder, with a global prevalence of 14% (Am J Gastroenterol 2011; 106: 1582-1591) and, as is the case for most functional gastrointestinal (GI) disorders, it is more common in women (Aliment Pharmacol Ther 2014; 39: 312-321). Patients with constipation complain of a range of symptoms including hard or lumpy stools, decreased frequency of defecation, straining at stool, a feeling of incomplete evacuation, and some may also experience abdominal pain and bloating. The mainstay of treating constipation has been through changes to lifestyle, such as increasing dietary fiber intake, and the use of osmotic and stimulant laxatives. However, in recent years, a number of newer drugs with effects on GI motility, such as prucalopride, or intestinal fluid secretion, such as lubiprostone and linaclotide, have emerged.
PMID: 30659835 [PubMed - as supplied by publisher]